Cirrhosis nursing: lactulose titration, ascites, and SBP priorities

Approximately 4.5 million US adults (1.8%) carry a diagnosis of chronic liver disease, the population from which cirrhosis emerges. Chronic liver disease and cirrhosis caused 52,274 deaths in 2024, the ninth leading cause of death nationally (CDC FastStats), and it ranks among the top conditions nursing students will encounter on med-surg, ICU, and hepatology rotations. It is a chronic, progressive, and irreversible remodeling of the liver where repeated injury replaces functional hepatocytes with fibrotic scar tissue. Understanding the pathophysiology, recognizing the difference between compensated and decompensated stages, and knowing which complications require immediate intervention are all tested heavily on the NCLEX and essential in clinical practice.

This reference covers cirrhosis from the nursing perspective: what drives the disease process, how complications develop, priority assessments, interventions organized by complication, medications with nursing considerations, patient education, and NCLEX review tips. For scoring tools (Child-Pugh and MELD), hepatic encephalopathy grading, and hepatorenal syndrome details, see the liver failure nursing reference – this article cross-links rather than duplicating that content.

The transition from compensated to decompensated cirrhosis is a pivotal clinical event. Decompensation is defined by the first occurrence of ascites, variceal hemorrhage, hepatic encephalopathy, or jaundice. Once a patient crosses this threshold, the disease trajectory changes dramatically.

Pathophysiology: from injury to portal hypertension

Cirrhosis develops through a predictable cascade of cellular events, regardless of the underlying cause. Understanding this sequence helps you connect the disease mechanism to the clinical complications you will assess and manage.

Hepatocyte injury and stellate cell activation

Chronic liver injury – whether from alcohol, viral hepatitis, fatty liver disease, or autoimmune conditions – causes repeated hepatocyte death. Damaged hepatocytes release reactive oxygen species (ROS) and inflammatory cytokines (TGF-beta, TNF-alpha, interleukins). These signals activate hepatic stellate cells (HSCs), which are normally quiescent vitamin A-storing cells in the space of Disse.

Once activated, HSCs transform into myofibroblasts and begin depositing collagen (primarily types I and III) in the perisinusoidal space. This is the fibrosis stage. Concurrently, Kupffer cells (hepatic macrophages) amplify the inflammatory response, creating a self-perpetuating cycle of injury, inflammation, and fibrosis.

Fibrosis to regenerative nodules

As collagen accumulates, it disrupts the normal sinusoidal architecture. The liver attempts to regenerate, but new hepatocytes form within fibrous bands, creating regenerative nodules surrounded by scar tissue. These nodules lack normal vascular connections, so they function poorly despite being composed of living hepatocytes.

The structural distortion has two major consequences:

1. Increased intrahepatic resistance. Fibrotic tissue and regenerative nodules compress hepatic sinusoids and central veins, raising portal venous pressure. This is compounded by an imbalance in vasoactive mediators – cirrhotic sinusoidal endothelial cells produce less nitric oxide (a vasodilator) and more endothelin-1 (a vasoconstrictor), further increasing intrahepatic vascular resistance.

2. Loss of functional hepatocyte mass. As fibrosis progresses, fewer hepatocytes remain functional. Synthetic capacity declines: albumin production falls (causing edema and ascites), clotting factor production decreases (causing coagulopathy), and bilirubin conjugation fails (causing jaundice).

The portal hypertension cascade

Portal hypertension (portal venous pressure >5 mmHg, clinically significant at ≥10 mmHg) is the central driver of most cirrhosis complications. Elevated portal pressure forces blood through collateral pathways – portosystemic shunts that bypass the liver entirely. These collaterals form varices (esophageal, gastric, rectal), cause splenomegaly with resultant thrombocytopenia, and create caput medusae (visible periumbilical veins).

Simultaneously, splanchnic vasodilation from excessive nitric oxide production in the mesenteric circulation reduces effective circulating volume. The body compensates by activating the renin-angiotensin-aldosterone system (RAAS) and antidiuretic hormone (ADH), leading to sodium and water retention – the mechanism behind ascites and dilutional hyponatremia.

Causes of cirrhosis

The three most common causes in the United States are:

• Alcohol-related liver disease – develops after years of sustained heavy drinking; risk rises with the daily amount and the duration
• Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH) – the names that replaced NAFLD and NASH in the 2023 multisociety nomenclature, which also added MetALD for patients with both metabolic risk factors and increased alcohol intake. This is the fastest-growing cause, linked to obesity, type 2 diabetes, and metabolic syndrome
• Chronic hepatitis C – declining since the introduction of direct-acting antivirals but still prevalent

Other causes include chronic hepatitis B, autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency. In clinical practice, determining the etiology is essential because some causes are treatable (viral hepatitis, autoimmune hepatitis, Wilson disease), which can halt or slow progression.

Complications and nursing implications

Each major complication of cirrhosis has specific nursing assessment and intervention priorities. The complications below are organized from most common to most acutely life-threatening.

Ascites

Ascites is the most common complication of decompensated cirrhosis, occurring in approximately 60% of patients with compensated cirrhosis within 10 years of diagnosis. Fluid accumulates in the peritoneal cavity due to three converging mechanisms: portal hypertension pushing fluid out of the splanchnic vasculature, hypoalbuminemia reducing plasma oncotic pressure, and RAAS-driven sodium and water retention.

Nursing assessment: Measure abdominal girth daily at the same anatomical landmark (typically the umbilicus), with the patient supine. Track daily weights at the same time, on the same scale, wearing similar clothing. Strict intake and output documentation is essential. Assess for shifting dullness and fluid wave on physical exam. Monitor serum albumin, sodium, and renal function.

Management and nursing interventions:

• Sodium restriction: 2 g/day (2,000 mg). Educate the patient that most dietary sodium comes from processed foods, restaurant meals, and condiments – counting only “added salt” dramatically underestimates intake.
• Diuretics: The standard combination is spironolactone 100 mg plus furosemide 40 mg daily (the 100:40 ratio). This ratio maintains potassium balance because spironolactone is potassium-sparing while furosemide wastes potassium. Doses can be titrated upward together while maintaining this ratio (200:80, 400:160 maximum). Monitor potassium, sodium, creatinine, and daily weights. Target weight loss is 0.5 kg/day without peripheral edema, or 1.0 kg/day with peripheral edema.
• Therapeutic paracentesis: Large-volume paracentesis (LVP) is performed for tense or refractory ascites. When >5 L of fluid is removed, administer albumin 6–8 g per liter removed to prevent post-paracentesis circulatory dysfunction. Nursing care includes monitoring vital signs during and after the procedure, measuring the total volume drained, assessing the puncture site for leakage, and sending fluid for cell count, culture, and albumin (to calculate the serum-ascites albumin gradient, or SAAG).

Spontaneous bacterial peritonitis

Spontaneous bacterial peritonitis (SBP) is a bacterial infection of ascitic fluid without an identifiable surgical source. Bacterial infections are present in about one-third of hospitalized patients with cirrhosis, and spontaneous infections (SBP, spontaneous bacteremia, and spontaneous bacterial empyema) are the most common type, accounting for 36% of infections in a large prospective worldwide cohort. Up to a third of patients with a spontaneous infection have no abdominal symptoms and present only with encephalopathy or AKI.

Diagnosis: The 2021 AASLD guidance calls for a diagnostic paracentesis in every patient with cirrhosis and ascites who is hospitalized emergently, even without symptoms of infection, and whenever a patient with ascites develops fever, abdominal pain or tenderness, new or worsening encephalopathy, renal function decline, or unexplained clinical deterioration. The 2021 guidance sets the diagnostic threshold at an ascitic fluid polymorphonuclear neutrophil (PMN) count >250 cells/mm³ (the 2009 guideline wrote it as ≥250). Treatment begins immediately on clinical suspicion – do not wait for culture results.

Common organisms: Escherichia coli, Klebsiella pneumoniae, and streptococcal species (gram-negative organisms predominate).

Treatment: An IV third-generation cephalosporin is first-line for community-acquired SBP. The classic regimen from the 2009 AASLD guideline is cefotaxime 2 g every 8 hours for 5 days; the 2021 AASLD guidance gives cefotaxime 2 g every 12 hours as its example, for 5–7 days. Both regimens are in use, so follow the order and local protocol. Nosocomial or healthcare-associated SBP, recent broad-spectrum antibiotic exposure, or sepsis calls for broader empiric coverage. A repeat paracentesis at 48 hours showing a PMN fall of less than 25% signals treatment failure. IV albumin (1.5 g/kg on day 1 and 1.0 g/kg on day 3) is given with the antibiotics: the 2021 guidance recommends it for all patients with SBP, with the greatest benefit in those with AKI or jaundice, after the Sort trial showed it cut renal impairment (33% to 10%) and in-hospital mortality (29% to 10%). Non-selective beta-blockers are held temporarily if the patient with SBP becomes hypotensive (mean arterial pressure <65 mmHg) or develops AKI.

Prophylaxis (AASLD 2021): After a first episode of SBP, patients receive long-term daily antibiotic prophylaxis. Norfloxacin 400 mg daily is the agent studied in the original trials, but it was withdrawn from the US market in 2014, so the guidance accepts oral ciprofloxacin 500 mg daily instead. Trimethoprim-sulfamethoxazole is used by some clinicians, though the guidance notes high-quality data for it are lacking. Every patient with cirrhosis and upper GI bleeding should receive IV ceftriaxone 1 g every 24 hours for a maximum of 7 days. Primary prophylaxis can be considered when ascitic fluid protein is <1.5 g/dL combined with renal dysfunction (creatinine >1.2 mg/dL, BUN >25 mg/dL, or sodium <130 mEq/L) or liver failure (Child-Pugh score >9 with bilirubin >3 mg/dL).

Nursing priority: Suspect SBP early. Any change in mental status, unexplained fever, or abdominal tenderness in a patient with ascites warrants a call to the provider for diagnostic paracentesis. Delayed diagnosis increases mortality significantly.

Portal hypertension and esophageal varices

Portal hypertension drives the formation of esophageal and gastric varices – dilated, thin-walled veins that develop as collateral pathways for portal blood flow. Varices are present in approximately 50% of patients with cirrhosis at diagnosis, and a variceal bleed carries a 6-week mortality of about 15–20%.

Surveillance: Screening is now risk-based rather than universal. Under the Baveno VI/VII rule, patients with compensated disease, liver stiffness <20 kPa, and platelets ≥150,000/mm³ can skip screening EGD and repeat elastography and platelets yearly; a Baveno VIII faculty member described this rule as still valid after the March 2026 conference. Baveno VIII (2026) also uses non-invasive tests to classify portal hypertension: liver stiffness ≤15 kPa with platelets ≥150,000/mm³ rules out CSPH, and liver stiffness ≥25 kPa (in viral, alcohol-related, or non-obese MASLD disease) rules it in. Patients already taking a non-selective beta-blocker for CSPH do not need screening EGD, because the result would not change treatment. Others undergo EGD, with surveillance intervals set by variceal size and whether the cause of liver disease is controlled.

Primary prophylaxis: Non-selective beta-blockers (NSBBs) reduce portal pressure and decrease the risk of a first variceal bleed. The 2024 AASLD practice guidance (published online October 2023) names carvedilol as the preferred NSBB (typically 12.5 mg/day), because its additional alpha-1 blockade lowers portal pressure more than propranolol or nadolol do. The same guidance shifted the treatment goal: NSBBs are now started once clinically significant portal hypertension is identified, with the aim of preventing decompensation rather than only preventing a first bleed. Baveno VIII (2026) keeps this approach and does not recommend NSBBs for preventing decompensation in patients without CSPH. Endoscopic band ligation (EBL) remains the AASLD alternative for patients with high-risk varices who cannot tolerate beta-blockers.

Acute variceal bleeding: This is a medical emergency. For detailed nursing management of variceal hemorrhage – including Blakemore tube care, octreotide infusion, and emergent EBL – see the GI bleed nursing reference. Key nursing actions include establishing two large-bore IV lines, initiating volume resuscitation (transfuse conservatively – target hemoglobin 7–8 g/dL in cirrhosis to avoid raising portal pressure), administering IV octreotide, giving prophylactic IV ceftriaxone (1 g every 24 hours, maximum 7 days), and anticipating endoscopy within 12 hours.

TIPS (transjugular intrahepatic portosystemic shunt): TIPS is a radiologic procedure that creates a shunt between the portal and hepatic veins, reducing portal pressure. Indications include refractory variceal bleeding unresponsive to endoscopic therapy, refractory ascites, and Budd-Chiari syndrome. In high-risk patients with acute variceal bleeding, Baveno VIII recommends preemptive TIPS within 72 hours. Before an elective TIPS, the 2026 ACG guideline recommends starting rifaximin 14 days beforehand and continuing it for at least 6 months to prevent post-TIPS encephalopathy. Post-TIPS nursing considerations include monitoring for hepatic encephalopathy (the shunt diverts portal blood past the liver, increasing ammonia delivery to the brain), assessing for shunt thrombosis (worsening ascites or recurrent bleeding), and monitoring liver function labs (TIPS can worsen hepatic function in patients with advanced disease).

Hepatic encephalopathy

Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome caused by neurotoxins – primarily ammonia – that accumulate when the liver cannot clear them. Portosystemic shunting (whether natural collaterals or a TIPS procedure) compounds the problem by delivering ammonia-rich portal blood directly to systemic circulation.

For the complete West Haven grading system, precipitating factors, and nursing assessment details, see the hepatic encephalopathy section of the liver failure reference. Below are the cirrhosis-specific management priorities.

Precipitating factors to assess: GI bleeding (blood is a protein load that increases ammonia production), infection (including SBP), constipation, dehydration, electrolyte imbalances (particularly hypokalemia and metabolic alkalosis, which increase ammonia crossing the blood-brain barrier), sedative use (benzodiazepines, opioids), and excessive dietary protein.

Key assessment finding – asterixis: Asterixis (flapping tremor) is the hallmark sign of Grade 2 HE. To test, ask the patient to extend both arms with wrists dorsiflexed and fingers spread – an involuntary, irregular flapping indicates asterixis. This is a high-yield NCLEX item.

Management:

• Lactulose is first-line therapy. It works by two mechanisms: acidification of colonic contents (converts ammonia [NH3] to non-absorbable ammonium [NH4+], which is trapped in the gut lumen) and an osmotic laxative effect (speeds transit so the ammonium is expelled). Titration goal: 2–3 soft stools per day, the target in both the lactulose label and the 2026 ACG guideline, which adds the Bristol Stool Scale to stool counts. Too few stools means insufficient ammonia clearance; too many means risk of dehydration and electrolyte depletion, which can paradoxically worsen encephalopathy. Polyethylene glycol 3350 is an acceptable alternative when lactulose is not tolerated. This titration target is an NCLEX favorite.
• Rifaximin (550 mg twice daily) is added as adjunctive therapy to reduce ammonia-producing gut bacteria. It is a poorly absorbed antibiotic that acts locally in the GI tract. After a first episode, lactulose alone is the preferred preventive therapy; the 2026 ACG guideline recommends adding rifaximin for breakthrough episodes on lactulose and also supports adding it to lactulose during an acute overt episode.
• Dietary protein: Current guidelines recommend maintaining normal protein intake (1.2–1.5 g/kg/day) in most patients with HE. Protein restriction was formerly standard practice but is now discouraged because cirrhotic patients are already catabolic and protein-malnourished – restricting protein accelerates sarcopenia without meaningful ammonia reduction.
• Zinc supplementation is suggested by the 2026 ACG guideline for patients with documented zinc deficiency who are already on lactulose and rifaximin. Zinc is a cofactor for the urea-cycle enzyme ornithine transcarbamylase, and deficiency is common in cirrhosis.

Hepatorenal syndrome

Hepatorenal syndrome (HRS) is renal failure occurring in the context of advanced liver disease, without intrinsic kidney pathology. The kidneys themselves are structurally normal – the problem is extreme renal vasoconstriction driven by splanchnic vasodilation and reduced effective circulating volume. For detailed pathophysiology and classification, see the liver failure reference.

Current terminology: The International Club of Ascites replaced the older Type 1 and Type 2 labels in 2015. Rapidly progressive HRS is now called HRS-AKI, diagnosed by a creatinine rise of at least 0.3 mg/dL within 48 hours or at least 50% above baseline within 7 days, with no fixed creatinine cutoff required. The 2024 ADQI–International Club of Ascites consensus also accepts urine output ≤0.5 mL/kg/hr for ≥6 hours and no longer requires a fixed 48-hour albumin challenge before the diagnosis. The slower, ascites-associated form is now HRS-CKD. Older textbooks and question banks still use Type 1 and Type 2, so recognize both.

Nursing essentials: Monitor urine output hourly – oliguria (<400 mL/day) with low urine sodium (<10 mEq/L) in a cirrhosis patient should raise immediate suspicion for HRS. Trend serum creatinine. Avoid nephrotoxic medications (NSAIDs, aminoglycosides, IV contrast when possible). HRS-AKI (classic type 1 HRS historically had a median survival of about 2 weeks without treatment) is an emergency requiring vasoconstrictor therapy with albumin. Terlipressin (Terlivaz) was FDA-approved in September 2022 and is the only agent licensed in the US for this indication. Its label carries a boxed warning for serious or fatal respiratory failure: patients with volume overload or grade 3 acute-on-chronic liver failure are at higher risk, SpO2 is checked before the first dose, the drug is not started if SpO2 is <90%, and oxygenation is monitored continuously. Patients with serum creatinine >5 mg/dL are unlikely to benefit. Norepinephrine with albumin (in the ICU) is the other effective option; midodrine plus octreotide is still used where neither is available, but AASLD 2021 notes it is much less effective than terlipressin.

Coagulopathy

The liver synthesizes nearly all clotting factors (I, II, V, VII, IX, X, XI, XII, XIII) plus anticoagulant proteins (protein C, protein S, antithrombin). Cirrhosis creates a complex coagulation state – patients are at increased risk of both bleeding (reduced factor synthesis, thrombocytopenia from hypersplenism) and thrombosis (reduced protein C and S).

Nursing actions: Monitor INR, PT, PTT, fibrinogen, and platelet count trending. Implement bleeding precautions: soft toothbrush, electric razor, avoid rectal temperatures, hold pressure on venipuncture sites for at least 5 minutes, and minimize unnecessary needle sticks. Assess for bleeding signs – melena, hematemesis, hematuria, petechiae, ecchymoses, gingival bleeding. Vitamin K may be administered but only helps if the liver retains enough functional capacity to synthesize clotting factors. An important guideline shift: because both procoagulant and anticoagulant factors fall together, the INR does not predict bleeding risk in cirrhosis, and the AASLD 2020 vascular liver disorders guidance (published 2021) recommends against routine pre-procedure correction of INR, platelet count, or fibrinogen in patients not taking a vitamin K antagonist. Fresh frozen plasma (FFP) and cryoprecipitate are reserved for active bleeding rather than given prophylactically to normalize a number – prophylactic FFP carries volume-overload and transfusion risks without proven benefit. Review the lab values cheat sheet for coagulation panel normal ranges.

Malnutrition and sarcopenia

Malnutrition is common in cirrhosis, more so in decompensated disease, and EASL 2019 links it to infection, encephalopathy, ascites, and lower survival. Mechanisms include poor oral intake (early satiety from ascites, dysgeusia, nausea), impaired nutrient absorption, increased resting energy expenditure, and impaired hepatic glycogen storage causing accelerated starvation physiology – cirrhotic patients begin gluconeogenesis from amino acids after just an overnight fast (compared to ~72 hours in healthy individuals).

Nursing interventions: Encourage small, frequent meals (4–6 per day) to avoid prolonged fasting. A late-evening snack (before bed) is specifically recommended to reduce overnight catabolism and has been shown to improve nitrogen balance. EASL 2019 recommends at least 35 kcal/kg/day (actual body weight) for non-obese patients. Protein intake should be maintained at 1.2–1.5 g/kg/day. Consult a dietitian early. Monitor prealbumin for shorter-term nutritional trends (half-life ~2 days) rather than albumin (half-life ~21 days).

Nursing assessment priorities

A focused assessment for the cirrhosis patient integrates findings from every organ system affected by portal hypertension and hepatocellular failure. Use the head-to-toe assessment framework and look specifically for the following:

Neurological: Assess orientation and cognition at every shift. Test for asterixis. Monitor for sleep-wake cycle reversal, personality changes, slowed responses – these may be the earliest signs of encephalopathy that family members notice before nursing staff. Use the Glasgow Coma Scale for grade 3–4 encephalopathy.

Integumentary: Inspect for jaundice (scleral icterus appears before skin changes), spider angiomas (most common on face, neck, upper chest, and arms), palmar erythema, caput medusae (dilated periumbilical veins), bruising, petechiae, excoriation from pruritus, and peripheral edema (sacral in bedridden patients, pedal in ambulatory patients).

Abdominal: Assess abdominal girth (document landmark used), auscultate bowel sounds (hypoactive in severe ascites), palpate for hepatomegaly (early cirrhosis) or a small, shrunken liver (late cirrhosis), assess for shifting dullness and fluid wave, and inspect for caput medusae and umbilical hernia (common with tense ascites).

Cardiovascular: Hyperdynamic circulation is common in advanced cirrhosis – tachycardia with bounding pulse and low blood pressure from splanchnic vasodilation. Orthostatic hypotension may indicate volume depletion or over-diuresis.

Renal: Strict intake and output. Monitor urine color and output hourly if HRS is a concern. Track daily weights. Monitor BUN, creatinine, and serum sodium (dilutional hyponatremia is common and a poor prognostic sign).

Musculoskeletal: Assess muscle mass, grip strength, and functional status. Sarcopenia (muscle wasting) is prevalent and affects prognosis. Temporal muscle wasting is an early visible indicator.

Nursing interventions by complication

Medications table

Patient education

Patient education in cirrhosis must be practical, specific, and repeated at every encounter because hepatic encephalopathy can impair the patient’s ability to retain information. Include family members and caregivers in all teaching sessions.

Dietary guidance: Adhere to a 2 g/day sodium restriction. Read food labels – aim for <600 mg sodium per meal. Maintain adequate protein intake (1.2–1.5 g/kg/day) despite previous teaching that may have emphasized protein restriction. Eat small, frequent meals and include a bedtime snack to prevent overnight muscle breakdown. Avoid raw or undercooked shellfish, especially oysters. Liver disease raises the risk of severe Vibrio infection, and CDC reports that about 1 in 5 people with Vibrio vulnificus infection die.

Alcohol avoidance: Complete and permanent abstinence is essential regardless of cirrhosis etiology. Even moderate alcohol consumption accelerates fibrosis in all forms of liver disease. Refer to substance use counseling and community support resources.

Medication adherence: Take lactulose as prescribed and report to the provider if stool frequency drops below 2 or stays above 3 per day. Take diuretics in the morning to avoid nocturia. Avoid all NSAIDs (ibuprofen, naproxen, aspirin) – these impair renal perfusion and increase GI bleeding risk. Acetaminophen is permitted but limited to <2 g/day in cirrhosis. Avoid herbal supplements unless approved by the hepatologist – many are hepatotoxic.

When to seek emergency care: Vomiting blood or passing black tarry stools, sudden abdominal swelling with fever or pain, confusion or difficulty concentrating (family should be educated on recognizing early encephalopathy), decreased urine output, or falls.

Surveillance: Patients need regular follow-up including variceal screening (EGD every 1–3 years depending on findings), hepatocellular carcinoma screening (abdominal ultrasound and alpha-fetoprotein every 6 months), and lab monitoring (liver function tests, CBC, renal panel, ammonia as indicated).

NCLEX tips

1. Compensated vs. decompensated: Know the difference. Compensated cirrhosis may be asymptomatic – decompensation begins with the first episode of ascites, variceal bleeding, encephalopathy, or jaundice. This distinction drives nursing priorities.

2. Asterixis = encephalopathy sign: Test for asterixis by having the patient dorsiflex the wrists with arms extended and fingers spread. A flapping tremor indicates Grade 2 or higher hepatic encephalopathy. High-yield NCLEX finding.

3. Lactulose titration target: 2–3 soft stools per day. If the patient has fewer than 2, the dose is too low. Frequent watery stools risk dehydration and electrolyte imbalances that can worsen encephalopathy. Know this number.

4. Spironolactone:furosemide ratio is 100:40. This maintains potassium balance. If a question asks about diuretic therapy in cirrhotic ascites, look for this pairing and ratio.

5. SBP diagnostic threshold: PMN >250 cells/mm³ in ascitic fluid (AASLD 2021). Treatment starts immediately on suspicion – antibiotics and albumin. A patient with ascites who develops fever and confusion needs diagnostic paracentesis urgently.

6. Hepatorenal syndrome = functional renal failure. The kidneys are structurally normal. Low urine sodium (<10 mEq/L) and oliguria in a cirrhosis patient should trigger concern. HRS-AKI (formerly Type 1) is rapidly progressive and life-threatening.

7. Avoid NSAIDs in cirrhosis. NSAIDs impair renal prostaglandin-mediated perfusion and increase GI bleeding risk. For pain, acetaminophen <2 g/day is preferred. This comes up frequently in NCLEX medication questions.

8. Post-paracentesis albumin: When >5 L is removed during large-volume paracentesis, administer albumin 6–8 g per liter removed. Without albumin replacement, post-paracentesis circulatory dysfunction can cause renal failure.

9. Protein restriction is outdated. Current evidence supports maintaining protein intake at 1.2–1.5 g/kg/day in hepatic encephalopathy. Restricting protein worsens sarcopenia and outcomes. If a question offers protein restriction as a nursing intervention, it is likely the distractor.

10. TIPS increases encephalopathy risk. A TIPS procedure shunts portal blood past the liver, increasing ammonia delivery to the brain. Any patient post-TIPS needs increased neurological monitoring; the 2026 ACG guideline starts rifaximin 14 days before an elective TIPS.

Related pages

• Liver failure nursing: assessment, interventions, and complications – Child-Pugh scoring, MELD score, hepatic encephalopathy grading, hepatorenal syndrome details
• GI bleed nursing: assessment, interventions, and clinical management – variceal hemorrhage management, Blakemore tube, octreotide
• Pancreatitis nursing – alcohol-related pancreatitis frequently co-occurs with cirrhosis
• Nursing lab values cheat sheet – liver function tests, coagulation panel, CBC normal ranges
• Electrolyte imbalances nursing reference – hyponatremia, hypokalemia, and hyperkalemia management in cirrhosis
• ABG interpretation – respiratory alkalosis (common in cirrhosis from hyperventilation) and metabolic alkalosis
• Head-to-toe assessment – systematic physical assessment framework
• ADPIE nursing process – structured care planning for complex patients
• SBAR communication – critical for escalating encephalopathy or variceal bleeding
• Glasgow Coma Scale – neurological assessment for grade 3–4 encephalopathy
• Drug classifications nursing – diuretics, beta-blockers, antibiotics
• Sepsis nursing – SBP can progress to sepsis in cirrhosis patients

References

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024
2. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–735. doi:10.1002/hep.27210
3. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081. doi:10.1056/NEJMoa0907893
4. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–409. doi:10.1056/NEJM199908053410603
5. de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop – stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752. doi:10.1016/j.jhep.2015.05.022
6. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–1048. doi:10.1002/hep.31884
7. Kaplan DE, Ripoll C, Thiele M, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(5):1180–1211. doi:10.1097/HEP.0000000000000647
8. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968–974. doi:10.1016/j.jhep.2014.12.029
9. Córdoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38–43. doi:10.1016/j.jhep.2004.03.023
10. Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38(2):485–521. doi:10.1016/j.clnu.2018.12.022
11. González-Abraldes J, Albillos A, Bañares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology. 2001;121(2):382–388. doi:10.1053/gast.2001.26288
12. Ginès P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839–1847. doi:10.1053/gast.2002.37073
13. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172–1181. doi:10.1002/hep.24786
14. Northup PG, Garcia-Pagán JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366–413. doi:10.1002/hep.31646
15. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–828. doi:10.1056/NEJMoa2008290
16. Centers for Disease Control and Prevention, National Center for Health Statistics. FastStats: chronic liver disease and cirrhosis (2024 mortality data; 2018 NHIS prevalence). Hyattsville, MD: NCHS; accessed October 17, 2026.
17. Centers for Disease Control and Prevention. About Vibrio infection. Atlanta, GA: CDC; accessed October 17, 2026. https://www.cdc.gov/vibrio/about/index.html
18. Ignatavicius DD, Workman ML, Rebar CR. Medical-Surgical Nursing: Concepts for Interprofessional Collaborative Care. 10th ed. St. Louis: Elsevier; 2021.
19. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–2107. doi:10.1002/hep.22853 [Superseded by ref 6; cited only as the source of the cefotaxime 2 g every 8 hours regimen]
20. Baveno VIII Faculty. Baveno VIII – advancing consensus in portal hypertension. J Hepatol. 2026;85(5):993–1018. doi:10.1016/j.jhep.2026.07.030
21. Merli M, Berzigotti A, Zelber-Sagi S, et al; European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–193. doi:10.1016/j.jhep.2018.06.024
22. Nadim MK, Kellum JA, Forni L, Francoz C, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol. 2024;81(1):163–183. doi:10.1016/j.jhep.2024.03.031
23. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. doi:10.1097/HEP.0000000000000520
24. Bajaj JS, Jakab SS, Jesudian AB, Rahimi RS, Duarte-Rojo A, et al. ACG clinical guideline: hepatic encephalopathy. Am J Gastroenterol. 2026;121(3):588–618. doi:10.14309/ajg.0000000000003899
25. TERLIVAZ (terlipressin) for injection. US prescribing information (boxed warning: serious or fatal respiratory failure). Mallinckrodt Hospital Products; DailyMed, published June 2026.
26. Lactulose solution, USP (Enulose). US prescribing information: dosage and administration for portal-systemic encephalopathy. Actavis Pharma; DailyMed.
27. American Gastroenterological Association. Baveno VIII shifts portal hypertension care toward prevention. GI & Hepatology News. September 2026. https://news.gastro.org/issues/2026/september-2026/baveno-viii-shifts-portal-hypertension-care-toward-prevention/